Kodiak Sciences (KOD) Why AMD fueled the stock 180% Higher
Kodiak Sciences stock surged over 170 percent following positive Phase 3 trial results for its wet age-related macular degeneration treatments, Zenkuda and KSI-501.
Kodiak Sciences stock surged over 170 percent following positive Phase 3 trial results for its wet age-related macular degeneration treatments, Zenkuda and KSI-501.
Kodiak Sciences stock surged over 170 percent following positive Phase 3 trial results for its wet age-related macular degeneration treatments, Zenkuda and KSI-501.
JP Morgan has maintained its buy rating on Microsoft stock and set an ambitious price target of $625, as shares surpass the $500 threshold amid strong…
Advanced Micro Devices, Inc (AMD) stock price closed 3.61% (22.76 points) lower on Monday, September 28, 2026. The…
META stock falls from a peak of $779 to $715 after its Muse AI agent inadvertently leaked a user's home address on Facebook Marketplace, sparking serious…
Hyperliquid native token HYPE slipped out of the top ten cryptocurrencies after a 6.5% weekly crash. The downturn follows a record-breaking peak of $97.96, profit-taking, and…
Discover how investing $100 monthly in AMD stock through September 2030 could yield a portfolio value ranging from $3,233 to $6,450 based on current projections.